Cerenome, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CNSY | RADX | CLRB | LTRN | PCSA | UKJ0.F | |
|---|---|---|---|---|---|---|
| Market cap | 6.77M | 13.65M | 11.63M | 8.76M | 5.41M | 6.29M |
| P/E (TTM) | — | — | — | — | — | 0.0 |
| Forward P/E | -0.4 | -0.4 | -0.6 | -0.3 | -0.5 | — |
| Price/book | 1.2 | 0.6 | 0.3 | -2.3 | -17.0 | 0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −93.02% | −80.82% | −64.14% | −82.53% | −75.51% | −98.81% |
| Today | −31.42% | −2.37% | −6.11% | −2.61% | −0.26% | +21.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CNSY news ›Cerenome Inc. (CNSY) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Cerenome Inc. market cap is $12.98M. 52 week high…
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be held on November 12-15 in Philadelphia…
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration Expands CNSide contracted payer access to approximately 164 million covered lives HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) --…
Cerenome Launches CNSide® CSF Molecular Profile Tests
HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based…
Cerenome, Inc. Enters Into Up To $20 Million Senior Secured Financing Facility With 3i, LP With Royalty-Based Repayment
Cerenome, Inc. entered into a financing agreement with 3i, LP for a senior secured facility of up to $20 million with royalty-based repayments. Under the agreement, the Company received initial... entered into a financing agreement with…
Transcript : Cerenome, Inc. - Special Call
Presentation Operator MessageOperator Good morning, and welcome to the Cerenome Third Quarter 2026 Business Update Conference Call. [Operator Instructions] Before we begin, we want to advise you Transcript : Cerenome, Inc. - Special Call…
Cerenome, Inc. announced that it expects to receive $20 million in funding from 3i Fund
Cerenome, Inc entered into a securities purchase agreement with 3i, LP managed by 3i Fund for a private placement to issue senior secured convertible notes in the aggregate original principal amount... Cerenome, Inc entered into a…
Cerenome Reports Preclinical Data Suggesting Dual Mechanism of REYOBIQ and Enhanced Antitumor Activity with Checkpoint Blockade
Cerenome announces dual mechanisms of action for REYOBIQ in cancer treatment, enhancing effectiveness when combined with checkpoint blockade. New findings suggest that REYOBIQ has a dual mechanism of action that enhances its therapeutic…
Cerenome Launches Two CSF Molecular Profiling Tests for CNS Cancers
Oct 7, 2026 | Cancer, Molecular Diagnostics | CNSide Diagnostics, a subsidiary of Cerenome, has commercially launched two new cerebrospinal fluid (CSF)-based molecular profiling tests for central nervous system (CNS) oncology. Available to…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com8
- marketscreener.com6
- manilatimes.net1
- stocktitan.net1
- stocktwits.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.